Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Differences In Amphetamine/Dextroamphetamine Prescriptions In Areas With & Without Large Universities, Heather Bacon
Differences In Amphetamine/Dextroamphetamine Prescriptions In Areas With & Without Large Universities, Heather Bacon
Honors Theses
This investigative study is examining trends in stimulant prescribing for several Michigan counties. An ex-post facto design was used to determine trends in the amount of amphetamine/dextroamphetamine dispensed in four Michigan counties containing large universities and two Michigan counties not containing large universities over the years 2007-2012. The study found suggestive evidence that there is an increasing trend of amphetamine/dextroamphetamine prescriptions filled in both counties with and without large universities. Suggestive evidence was also found that counties with large universities display a greater average amount of amphetamine/dextroamphetamine dispensed than counties without large universities for the years 2007-2012. Because the study …
Crizotinib: A Tyrosine Kinase Inhibitor, Graham Mclaren
Crizotinib: A Tyrosine Kinase Inhibitor, Graham Mclaren
Honors Theses
Crizotinib is a small molecule tyrosine kinase inhibitor that is currently being marketed by Pfizer under the trade name Xalkori®. After its development in 2005, an appropriate target was discovered in 2007. By 2011 the FDA had approved crizotinib for use in patients with ALK+ non small cell lung cancer (NSCLC). ALK+ NSCLC is caused by a genetic mutation that truncates and flips a section of the EML4 gene and attaches it to a section of the ALK gene. The result is the EML4-ALK oncogene. The resulting protein from this mutation is capable of undergoing ligand independent dimerization, …